Treatment Pathway
Treatment of Cardiac Arrhythmia
Cardiac arrhythmia refers to irregular heart rhythms — the heart beats too fast, too slow, or with an irregular pattern. Some arrhythmias are harmless, while others (like atrial fibrillation) significantly increase the risk of stroke and heart failure.
ESC (European Society of Cardiology)ACC/AHA (American Heart Association)NICE (UK)WHO Cardiovascular Guidelines
Managing Cardiac Arrhythmia effectively requires a combination of medical treatment, lifestyle modification, and regular monitoring. With a structured management plan, most people with Cardiac Arrhythmia can maintain a good quality of life and prevent serious complications.
First-Line Treatment Principles
- ✓Risk factor modification: target BP <130/80 mmHg in most patients, LDL according to risk category
- ✓Antiplatelet therapy (aspirin or P2Y12 inhibitor) for established atherosclerotic disease
- ✓ACE inhibitor or ARB for heart failure with reduced ejection fraction (HFrEF) and post-MI LV dysfunction
- ✓Beta-blocker for rate control, post-MI, and stable HFrEF
- ✓Statin therapy for all patients with established ASCVD or high CV risk
What to Do Now
- Learn your personal risk factors for Cardiac Arrhythmia (family history, age, lifestyle)
- Attend regular health check-ups and screening tests appropriate for your age and risk
- Track new or changing symptoms, especially those associated with Cardiac Arrhythmia
- Use our AI symptom checker to assess whether your symptoms fit an early Cardiac Arrhythmia pattern
- Discuss preventive strategies and early monitoring with your GP
- Build a personalised management plan with your GP or specialist
- Adhere consistently to prescribed medications — do not stop without medical advice
- Adopt a Cardiac Arrhythmia-appropriate diet (anti-inflammatory, low-glycaemic, or disease-specific)
Non-Pharmacological Management
- •Cardiac rehabilitation program after MI, HF, or revascularisation
- •Dietary modification: Mediterranean or DASH diet; restrict sodium <2g/day in HF
- •Regular aerobic exercise: 150 min/week moderate intensity (when stable)
- •Smoking cessation — reduces CV event risk by 30–50% within 1 year
- •Weight management: target BMI 20–25 kg/m²
- •Alcohol restriction: ≤2 units/day men, ≤1 unit/day women
- •Stress reduction and sleep optimisation
Treatment Goals
🎯Prevention of major adverse cardiovascular events (MACE): MI, stroke, CV death
🎯Symptom control: absence of angina, dyspnoea, oedema
🎯Preservation or improvement of left ventricular function
🎯Quality of life improvement; functional capacity (NYHA class I–II)
🎯Target organ protection: renal function, cognitive function, peripheral vasculature
Monitoring Parameters
- ◆BP and heart rate at every clinical visit
- ◆ECG: at baseline, after medication changes, and when symptomatic
- ◆Echocardiogram: for HF monitoring (EF, wall motion) — annually or after therapy change
- ◆Lipid panel: 4–12 weeks after statin initiation or dose change; then annually
- ◆Renal function and electrolytes (eGFR, K+): within 1–2 weeks of starting ACE inhibitor/ARB/diuretic
- ◆HbA1c if diabetic (target <7%); weight and fluid balance in HF
- ◆INR monitoring for warfarin therapy (target INR 2–3 for most indications)
Red Flags — When to Escalate
- ⚠Any of the characteristic symptoms of Cardiac Arrhythmia — even mild — in a high-risk individual
- ⚠Progressive worsening of early warning signs over weeks
- ⚠Laboratory abnormalities (e.g., blood sugar, inflammatory markers) without full symptoms
- ⚠Unexplained weight loss, night sweats, or fatigue persisting >2 weeks
- ⚠Strong family history of Cardiac Arrhythmia combined with new relevant symptoms
- ⚠Sudden worsening of Cardiac Arrhythmia symptoms despite established treatment
Escalation Criteria
- →Refractory angina despite maximal medical therapy → invasive assessment (coronary angiography)
- →Worsening HF despite GDMT → device therapy consideration (ICD, CRT) or specialist referral
- →Uncontrolled BP >180/110 on ≥3 agents → secondary hypertension workup
- →New or worsening arrhythmia → cardiology review
- →Acute coronary syndrome: activate emergency pathway immediately
Special Populations
Elderly: start at lower doses; monitor for orthostatic hypotension, renal impairment, and electrolyte disturbances
Diabetes: SGLT2 inhibitors and GLP-1 RAs have established CV benefit in addition to glucose lowering
CKD: ACE inhibitor/ARB renoprotective; avoid NSAIDs; adjust drug doses for eGFR
Pregnancy: many CV drugs contraindicated (ACE inhibitors, statins, warfarin) — specialist review essential
Clinical Insights
Not sure about your symptoms?
Our AI Symptom Checker analyses your symptoms and suggests the most likely diagnoses — including relevant treatment pathways.
Use AI Symptom Checker →